'Net sales (including other operating income) of
Epigral has declined 6.18% to Rs 587.36 crore.
Operating profit margin has declined from 28.50% to
22.53%, leading to 25.82% decline in operating profit to Rs 132.36 crore.
Raw material cost as a % of total sales (net
of stock adjustments) increased from 52.96% to 57.31%. Employee cost increased from 4.32% to 5.17%. Other expenses rose from 14.13% to
15.78%. Power and Oil fuel cost rose from
5.01% to 6.56%.
Other income fell 68.65% to Rs 1.74 crore.
PBIDT fell 27.11% to Rs 134.1 crore. Provision for interest fell 20.06% to Rs
21.84 crore. Loan funds declined from Rs
896.36 crore as of 30 September 2024 to Rs 537.15 crore as of 30 September
2025. Inventories rose to Rs 344.18
crore as of 30 September 2025 from Rs 336.65 crore as of...
Pleaselogin & subscribe to view the full report.
More Reports
-
(13-Jan-2026)
HCL Technologies
Revenue up 13.3% YoY to Rs 33872 crore in Q3FY2026
-
(13-Jan-2026)
Tata Consultancy Services
Revenue up 4.9% YoY to Rs 67087 crore in Q3FY2026
-
(12-Jan-2026)
Krishana Phoschem
Revenue up 116.8% YoY to Rs 659 crore in Q3FY2026
-
(11-Jan-2026)
Avenue Supermarts
Revenue up 13.3% YoY to Rs 18100.9 crore, Net profit up 18.3% yoy to Rs 855.9 crore in Q3FY2026
|
|